Report #2831986

Overview

Sex

Unknown

Age

Age unknown

State

CO

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

Priorix given intramuscularly, instead subcutaneous; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Priorix given intramuscularly, instead subcutaneous). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-MAR-2025 The registered pharmacist reported that a pharmacist stated to them that they had a Priorix given intramuscularly instead of subcutaneous, which led to subcutaneous injection formulation administered by other route The reporter was just wondering does it need to be readministered or was still effective.